19:21 , Jan 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Allergy Cell culture studies suggest a CD23-mimicking single-domain antibody against IgE could help treat allergy. The single-domain neutralizing antibody mimics CD23, the low-affinity Fc receptor for IgE, to bind IgE with a K d...
21:17 , Oct 26, 2017 |  BC Innovations  |  Translation in Brief

An adjuvant to remember

A team from The Rockefeller University has borrowed a leaf from bispecific T cell engagers to create a strategy for engaging B cells to enhance responses to the seasonal flu vaccine. The group created a...
16:56 , Oct 17, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus Mice studies suggest CD23 -activating, bispecific antibodies against two HA epitopes could help boost responses to seasonal influenza vaccines. Bispecific antibodies were engineered against the stem and globular domains of HA, then...
07:00 , May 21, 2015 |  BC Innovations  |  Translation in Brief

Formula's Italian CAR

Formula Pharmaceuticals Inc. has licensed a chimeric antigen receptor (CAR) technology from Fondazione Matilde Tettamanti Menotti De Marchi Onlus that it thinks will be safer and more efficient than other CAR T cell approaches because...
07:00 , Jul 21, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic lymphocytic leukemia (CLL); hairy cell leukemia CD160; CD23; CD5 Human studies suggest CD160 expression could help diagnose CLL. In mature and immature B cells...
07:00 , Oct 26, 2009 |  BC Week In Review  |  Clinical News

Lumiliximab: Suspended Phase II/III enrollment

Biogen Idec disclosed that it stopped recruitment in the Phase II/III LUCID trial of lumiliximab to treat CLL after a strategic review of the program determined that the trial would not support registration of the...
00:45 , Oct 21, 2009 |  BC Extra  |  Company News

Biogen Idec discloses pipeline setbacks

Biogen Idec Inc. (NASDAQ:BIIB) disclosed setbacks for three compounds during its 3Q09 earnings conference call on Tuesday: ocrelizumab, lumiliximab and galiximab. The biotech said that it placed the Phase III FILM trial of ocrelizumab to...
08:00 , Jan 21, 2008 |  BC Week In Review  |  Clinical News

Lumiliximab regulatory update

EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for lumiliximab to treat chronic lymphocytic leukemia (CLL). The anti- CD23 mAb, which has Fast Track and Orphan designations...
08:00 , Feb 12, 2007 |  BC Week In Review  |  Clinical News

Lumiliximab regulatory update

FDA granted Orphan Drug and Fast Track designations for lumiliximab to treat relapsed or refractory chronic lymphocytic leukemia (CLL). Lumiliximab is a monoclonal antibody against CD23 . Biogen Idec Inc. (BIIB), Cambridge, Mass.   Product:...
08:00 , Feb 12, 2007 |  BC Week In Review  |  Clinical News

Lumiliximab: Phase II/III started

BIIB began the open-label, U.S. and Australian Phase II/III LUCID trial in about 276 patients. The trial will compare lumiliximab plus fludaribine, cyclophosphamide and rituximab (FCR) with FCR alone. Rituxan rituximab is marketed by BIIB,...